You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020258016
Dec 20204406
Jan 20213006
Feb 202127015
Mar 202188015
Apr 202176015
May 202127015
Jun 20210014
Jul 20210011
Aug 20210011
Sep 2021003
Oct 202180033
Nov 202166013
Dec 20213007
Jan 202218804
Feb 202264011
Mar 202211509
Apr 202211607
May 20229008
Jun 2022104012
Jul 202212008
Aug 20228006
Sep 20225404
Oct 20225402
Nov 20226003
Dec 20227604
Jan 20235403
Feb 20236200
Mar 20238404
Apr 20232406
May 20233607
Jun 20232604
Jul 20232804
Aug 20231805
Sep 20233003
Oct 20234004
Nov 20237807
Dec 202314207
Jan 20241600
Feb 20245802
Mar 20243602
Apr 20243406
May 20247404
Jun 20246903
Jul 20244009
Aug 20242305
Sep 20242003
Oct 20243204
Nov 20242406
Dec 20243408
Jan 20252006
Mar 2025005
Apr 2025004
May 2025004
Jun 2025006
Total29490389